Himalaya Therapeutics has xclusive access in China to BioAtla’s “CAB” therapeutics to treat cancer
Employees: 1-10
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | SeedFolio | seedfolio.... |
Mentions in press and media 8
| Date | Title | Description |
| 08.11.2022 | Himalaya Therapeutics Announces Highlights of Recent Clinical Progress | Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled HTBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated ... |
| 12.09.2022 | Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011) | Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 Undifferentiated Pleomorphic Sarcoma ("UPS") and oste... |
| 05.10.2021 | Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC | SHANGHAI and SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China, of a novel class of investigational... |
| 23.08.2021 | Himalaya Therapeutics Announces Registration of its Office in Shanghai | |
| 23.08.2021 | Himalaya Therapeutics Announces Registration of its Office in Shanghai | SHANGHAI and SAN DIEGO, Aug. 23, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China, of a novel class of investigationa... |
| 06.05.2021 | Himalaya Therapeutics Announces Appointment of Howe Li as Chief Medical Officer | SAN DIEGO, May 6, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody thera... |
| 03.05.2021 | Himalaya Therapeutics Announces Appointment of Howe Li as Chief Medical Officer | |
| 19.04.2021 | Himalaya Therapeutics Announces Appointment of Nicholas Desjardins as Chief Financial Officer | SAN DIEGO, April 19, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody th... |